Salicylic acid plant ramp-up delays
The salicylic acid plant is still in stabilization; delays in achieving 800 tons/month breakeven could pressure margins.
AARTIDRUGS / bear-case history
Track the concerns that keep returning.
Aarti Drugs · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
Domestic antibiotic demand weakness
Domestic demand, especially in antibiotics, remained soft with slight degrowth; recovery expected only from Q4.
Pricing pressure on methylamines
Management acknowledged potential price erosion as new methylamine capacity comes online, which could impact margins.
Tarapur plant closure risk
Voluntary closure of chlorosulfonation process at Tarapur due to gas leak; though no material impact currently, regulatory delays could affect operations.
Continued Chinese dumping in salicylic acid
Chinese dumping persists, pressuring realizations. Management plans to file anti-dumping application by April 2026, but relief may take 6-8 months.
Slow ramp-up of greenfield facilities
Salicylic acid plant ramp-up slower than expected due to technology changes and quality parameter adjustments, delaying profitability.
Antibiotic demand weakness
Weaker antibiotic demand reduced overall market pool, leading to lower capacity utilization and margin pressure. Management noted this as a key headwind.
High capex despite recent investments
Analyst raised concern about continued high capex (₹150-200 Cr/year) while new plants are still scaling up. Management defended citing smooth Sikar ramp-up and need for oncology investment.
Sustained high crude prices hurting antibiotic demand
If crude remains above $110-120, domestic antibiotic demand may decline due to price sensitivity, impacting volumes.
Salicylic acid plant turnaround delayed
Salicylic acid production remains shut due to equipment delays and variable losses; restart depends on successful installation and testing.
Methylamine ramp-up dependent on metformin expansion
Higher utilization of the methylamine plant requires commensurate metformin production expansion, which is still underway.
Geopolitical disruptions impacting raw material supply
West Asia war caused ammonia shortages in March; further escalation could disrupt key raw material availability.